|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Biological half-life||1-2 hours|
|CAS Registry Number|
|Molecular mass||331.46 g/mol|
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
- Clinical use 1
- Adverse effects 2
- History and development 3
- See also 4
- References 5
- External links 6
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). However, a year later, they sold rights of the Axid Oral Solution (including the issued patent protecting the product) to Braintree Laboratories.
Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.
- Famotidine, Pepcid AC, Pepcidine: another popular H2-receptor antagonist
- "Nizatidine". Livertox.nih.gov. Retrieved 2015-10-11.
- "United States Patent: 6930119". Patft.uspto.gov. Retrieved 2015-10-11.
- Axid @ FDA
- Axid Oral Solution